Systemic sclerosis & Raynaud's
Signalling profile of circulating leucocytes of subjects with Raynaud’s phenomenon in relation to systemic sclerosis: a pilot study
Authors' conclusion
The results give insights into the pathogenesis of SSc. Smad2/3, STAT3(pY705), STAT6, and STAT4 pathways may serve as novel SSc biomarkers.
Study context
- Population
- Raynaud's phenomenon (RP) patients undergoing nailfold videocapillaroscopy
- Participants
- 8 / 17 / 8
- Comparison
- RP subjects who developed SSc vs RP subjects who did not vs healthy controls
- SSc+n = 8
- SSc-n = 17
- Healthy controls (HCs)n = 8reference
- Outcome
- Phosphorylated signalling molecules in peripheral blood leucocyte subsets
Methodological detailspilot study, phosphospecific flow cytometry, 9-10 years follow-up of medical records
- Pilot study
- Phosphospecific flow cytometry
- 9-10 years follow-up of medical records
Main finding
As reported in the abstract
- No significant differences in pNF-κB and pSTAT3(pS727) levels
- SSc+ vs SSc-: P = 0.005
- SSc+ vs HCs: P = 0.034
- SSc+ vs HCs: P = 0.001
- SSc- vs HCs: P = 0.026
- SSc+ vs HCs: P = 0.017
- SSc+ vs SSc-: P = 0.006
- SSc+ vs HCs: P < 0.001
- SSc+ vs SSc-: P = 0.004
- SSc+ vs HCs: P = 0.037
- SSc+ vs SSc-: P = 0.007
Original publication
Signalling profile of circulating leucocytes of subjects with Raynaud’s phenomenon in relation to systemic sclerosis: a pilot study. Scand J Rheumatol. Published 4 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →